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Abstract
In clinical trials the comparison of two different populations is a frequently ad-
dressed problem. Non-linear (parametric) regression models are commonly used to
describe the relationship between covariates as the dose and a response variable in
the two groups. In some situations it is reasonable to assume some model parameters
to be the same, for instance the placebo effect or the maximum treatment effect. In
this paper we develop a (parametric) bootstrap test to establish the similarity of two
regression curves sharing some common parameters. We show by theoretical argu-
ments and by means of a simulation study that the new test controls its level and
achieves a reasonable power. Moreover, it is demonstrated that under the assumption
of common parameters a considerable more powerful test can be constructed com-
pared to the test which does not use this assumption. Finally, we illustrate potential
applications of the new methodology by a clinical trial example.
Keywords and Phrases: Similarity of regression curves, equivalence testing, parametric
bootstrap, nonlinear regression, dose finding studies
1 Introduction
Regression models are commonly used to describe the relationship between multiple covari-
ates and a response variable. In certain applications, more than one regression model is
available, such as when assessing the relationship between the covariates and the response
variables in more than one population (e.g. in males and females). It is then often of inter-
est to demonstrate the equivalence of the regression curves: If equivalence can be claimed,
conclusions can be drawn from the pooled sample and a single regression model is sufficient
to describe the data. This can be achieved by testing a suitable null hypothesis that the
distance between the regression curves (measured in an appropriate sense) is smaller than
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a pre-specified equivalence margin at a controlled Type I error rate. Note that the problem
of equivalence testing, as considered in this paper, is conceptually different from the more
frequent problem of testing for equality of curves and is much less studied in the literature
due to methodological difficulties.
The problem of testing for equality of regression models has been intensively discussed in
the nonparametric context and we refer to the recent work of Feng et al. (2015), which-
contains a rather comprehensive list of references. In applied regression analysis, however,
parametric models are usually preferred to a purely nonparametric approach as they ad-
mit a direct interpretation of the observed effects in terms of the model parameters. In
addition, the available information of the observations is increased by applying more effi-
cient estimation or test procedures, provided that the assumed model is valid. Despite its
importance, the problem of establishing equivalence of two parametric regression models
while controlling the Type I error rate has only recently found attention in the literature.
Using the intersection-union test device from Berger (1982), Liu et al. (2009) investigated
the assessment of non-superiority, non-inferiority and equivalence when comparing two re-
gression models over a restricted covariate region. Building upon this work, Gsteiger et al.
(2011) derived equivalence tests based on simultaneous confidence bands for nonlinear re-
gression models, with application to population pharmacokinetic analyses. Likewise, Bretz
et al. (2016) assessed the similarity of dose response curves in two non-overlapping sub-
groups of patients. Alternatively, Dette et al. (2018) suggested directly estimating the
distance between the regression curves and using a non-standard bootstrap test to decide
for equivalence of the two curves if the estimate is less than a certain threshold. Expand-
ing this approach, Moellenhoff et al. (2018) assessed the comparability of drug dissolution
profiles via maximum deviation, whereas Hoffelder (2018) demonstrated the equivalence of
dissolution profiles using the Mahalanobis distance; see also Collignon et al. (2018).
In these papers, the authors assumed that the regression models have different parameters
and can therefore be evaluated separately. In some applications, however, this assumption
cannot be justified and it is more reasonable to assume that the regression models may have
some common parameters. The total number of parameters to estimate is then reduced to
the common and remaining parameters of each model, affecting the asymptotic behavior
of the estimators. Consider, for example, the Phase II dose finding trial for a weight
loss drug described in Bretz et al. (2016). This trial aimed at comparing the dose response
relationship for two regimens administered to patients suffering from overweight or obesity:
Three doses each for once daily (o.d.) and twice daily (b.i.d.) use of the medication, and
placebo. It is reasonable to assume that the placebo response is the same under both the
o.d. and the b.i.d. regimen. Since the regression models typically used for dose response
modeling contain a parameter for the placebo response (Pinheiro et al. (2006)), they will
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thus share this common parameter for both the o.d. and the b.i.d. regimen. In some
instances, it might even be reasonable to assume that the maximum efficacy for high doses
is similar in both groups. Moreover, clinical trial sponsors may even decide to use the same
placebo group for logistical reasons. The response of each patient on placebo is then used
twice in the estimation of the o.d. and b.i.d. dose response models, further complicating
the statistical problem.
In this paper, we investigate the equivalence of two parametric regression curves that share
common parameters. In Section 2 we first introduce the regression models to be estimated
under the assumption of common parameters. We then develop a non-standard bootstrap
test which performs the resampling under the constraints of the interval hypotheses implied
by the equivalence test problem. The new tests improves the procedure proposed in Dette
et al. (2018) using the additional information of common parameter in both groups. We also
discuss testing the equivalence of model parameters to assess whether the assumption of
common parameters is plausible. In Section 3 we investigate the finite sample properties of
the proposed bootstrap test proposed in terms of power and size. In Section 4 we illustrate
the methods using a multi-regional clinical trial example where it is conceivable that the
placebo and maximum treatment responses are the same across geographic regions but the
onset of treatment differs due to intrinsic and extrinsic factors (Malinowski et al. (2008);
ICH (2017)). Technical details and proofs are deferred to an appendix.
2 Methodology
2.1 Models with common parameters
Let
Y`,i,j = m`(d`,i, β`) + η`,i,j , j = 1, . . . , n`,i, i = 1, . . . , k`, (2.1)
denote the observed response of the jth subject at the ith dose level d`,i under the `th
dose response model m`, where ` = 1, 2 denotes the index of the two groups under con-
sideration. We assume that the (non-linear) regression model m` is parametrized through
a p`-dimensional vector β`, ` = 1, 2. Note that the regression models m1 and m2 may be
different. Likewise, the parameters β1 and β2 may be different even if m1 = m2. We further
assume that the error terms η`,i,j are independent and identically distributed with expec-
tation 0 and variance σ2` . The dose levels d`,i may be different in both groups but they are
attained on the same (restricted) covariate region D. In this paper D is assumed to be the
dose range, although the results can be generalized to include other covariates. Further,
n` =
∑k`
i=1 n`,i denotes the sample size in group ` where we assume n`,i observations in the
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ith dose level (i = 1, . . . , k`, ` = 1, 2). The sample sizes n` can be unequal and the total
number of observations is denoted by n = n1 + n2.
In this paper we consider the situation, where the regression models have some common
parameters. More precisely, we assume without loss of generality that these parameters
are given by the first p′ model parameters of the parameter β` in model (2.1) that is
β` = (β0, β˜`) ∈ Rp` , ` = 1, 2 , (2.2)
where β0 ∈ Rp′ denotes the vector of common parameters in both regression models and
β˜1 and β˜2 denote the remaining parameters in the models m1 and m2, respectively, which
do not necessarily coincide. The case where the models m1 and m2 do not share any
common parameters is included and corresponds to β` = β˜` for ` = 1, 2 (that is p
′ = 0). As
a consequence the p1+p2−p′-dimensional vector of all parameters of the regression functions
in model (2.1) under the assumption (2.2) is given by β = (β0, β˜1, β˜2). Throughout this
paper we assume that β ∈ B where B ⊂ Rp1+p2−p′ is a compact set.
These parameters are now estimated by least squares using the combined sample {Y`,i,j : j =
1, . . . , n`,i, i = 1, . . . , k`, ` = 1, 2}, that is
βˆ = (βˆ0,
ˆ˜β1,
ˆ˜β2) = arg min(b,,b˜1,,b˜2)∈B
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(
Y`,i,j −m`(d`,i, (b0, b˜`))
)2
. (2.3)
2.2 Testing equivalence of regression curves
Following Liu et al. (2009) and Gsteiger et al. (2011) we consider the regression curves m1
and m2 to be equivalent if the maximum distance between the two curves is smaller than
a given pre-specified constant, say ε > 0, that is,
d∞(β1, β2) = max
d∈D
|m1(d, β1)−m2(d, β2)| < ε.
In clinical trial practice ε is often referred to as a relevance threshold in the sense that if
d∞(β1, β2) < ε the difference between the two curves is believed not to be clinically relevant.
In order to establish equivalence of the two curves m1 and m2 at a controlled type I error,
we will develop a test for the hypotheses
H0 : d∞(β1, β2) ≥ ε versus H1 : d∞(β1, β2) < ε. (2.4)
In the following we extend the bootstrap approach from Dette et al. (2018) to test the
hypotheses (2.4) in the situation of common parameters. Note that the test procedure
proposed below could also be applied to alternative measures of equivalence, such as the
integrated deviation
∫
D |m1(t, β1)−m2(t, β2)|dt.
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Algorithm 2.1. (parametric bootstrap for testing equivalence under the assumption of
common parameters)
(1) Calculate the ordinary least-square (OLS) parameter estimate (2.3) assuming a com-
mon parameter β0. The corresponding variance estimates are given by
σˆ2` =
1
n`
k∑`
i=1
n`,i∑
j=1
(Y`,i,j −m`(d`,i, βˆ`))2, ` = 1, 2, (2.5)
where βˆ` = (βˆ0,
ˆ˜β`), ` = 1, 2. Calculate the estimate
dˆ∞ = d∞(βˆ1, βˆ2) = max
d∈D
|m1(d, βˆ1)−m2(d, βˆ2)|
for the maximal deviation between the two regression curves.
(2) Define the constrained estimates
ˆˆ
β` =
 βˆ` if dˆ∞ ≥ εβ¯` if dˆ∞ < ε , ` = 1, 2, (2.6)
where β¯1, β¯2 minimize the objective function in (2.3) under the additional restriction
d∞(β1, β2) = max
d∈D
|m1(d, β1)−m2(d, β2)| = ε. (2.7)
Define
ˆˆ
d∞ = d∞(
ˆˆ
β1,
ˆˆ
β2) and note that
ˆˆ
d∞ ≥ ε.
The next two steps describe the (parametric) bootstrap procedure.
(3) Generate data
Y ∗`,i,j = m`(d`,i, (
ˆˆ
β0,
ˆ˜ˆ
β`)) + η
∗
`,i,j , i = 1, . . . , n`,i, ` = 1, 2, (2.8)
with independent and normally distributed errors η∗`,i,j ∼ N (0, σˆ2` ).
(4) Calculate the OLS estimate βˆ∗ as in Step (1) and the test statistic
dˆ∗∞ = max
d∈D
|m1(d, βˆ∗1)−m2(d, βˆ∗2)|,
where β∗` = (β
∗
0 , β˜
∗
` ), ` = 1, 2. The α−quantile of the distribution of the distribution
of the statistic dˆ∗∞ is denoted by q
∗
α and the null hypotheses in (2.4) is rejected,
whenever
dˆ∞ < qˆ∗α. (2.9)
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In practice the qˆ∗α can be calculated repeating steps (3) and (4), say B times, in order to
obtain replicates dˆ∗∞,1, . . . , dˆ
∗
∞,B of dˆ
∗
∞. An estimate of qˆ
∗
α then is defined by qˆ
(B)
α := dˆ
∗(bBαc)
∞ ,
where dˆ
∗(1)
∞ ≤ . . . ≤ dˆ∗(B)∞ denotes the corresponding order statistic, and this estimate is
used in (2.9)
The following theorem states that this algorithm yields a valid test procedure. The proof
is left to the Appendix 6.
Theorem 2.1. The test defined by (2.9) is a consistent, asymptotic α-level test. That is
lim
n1,n2→∞
P
(
dˆ∞ < qˆ∗α
)
= 1, (2.10)
whenever d∞ < ε, and
lim sup
n1,n2→∞
P
(
dˆ∞ < qˆ∗α
) ≤ α. (2.11)
if d∞ ≥ ε.
Remark 2.2. The results presented in this section remain correct in trials with a common
placebo group, where n0 observations are taken at dose level d1 = 0 (corresponding to
placebo), which are modelled by the random variables Y0,1, . . . , Y0,n0 . For the sake of a
simple presentation we consider location-scale type models, such that the common effect at
the placebo can easily be modelled, but we note that more general models can be considered
as well introducing additional constraints for the parameter.
To be precise, we assume that the models in (2.1) are given by
m`(d, β`) = β0,1 + β˜`,1 ·m0`(d, β˜0` ), ` = 1, 2, i = 1, . . . , k`. (2.12)
where m0`(0, β˜
0
` ) = 0 (` = 1, 2), such that the condition m1(0, β`) = m2(0, β`) = β0,1 reflects
the fact that there is only one placebo group (and as a consequence a common placebo
parameter). Models of this type cover the most frequently used functional forms used in
drug development and several examples can be found in Ting (2006). Beside the location
parameter β0,1 there may be also other shared parameters, which we do not reflect in
our notations for a better readability. The `-th model is completely characterized by its
parameter β` = (β0, β˜`) = (β0, β˜`,1, β˜
0
` ), ` = 1, 2, and we obtain estimates of the model
parameters by minimizing the sum of squares
βˆ = (βˆ0,
ˆ˜β1,
ˆ˜β2) = arg minb∈B
n0∑
j=1
(
Y0,j−b0,1
)2
+
2∑
`=1
k∑`
i=2
n`,i∑
j=1
(
Y`,i,j−(b0,1+ b˜`,1 ·m0`(d`,i, b˜0`))
)2
.
(2.13)
Theorem 2.1 remains valid in this situation and a proof can be found in the Appendix (see
Section 6.4).
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2.3 Testing equivalence of model parameters
So far we assumed that the two regression models m1 and m2 share the common parameter
β0. In practice it may be necessary to assess whether this assumption is plausible using
an appropriate equivalence test for the shared model parameters. To be more precise, we
recall the definition the parameters β` in model (2.1), i.e.
β` = (β`,1, . . . , β`,p′ , . . . , β`,p`) , ` = 1, 2.
and note that assumption (2.2) of p′ common parameters in the models m1 and m2 can be
represented as (β1,1, . . . , β1,p′) = (β2,1, . . . , β2,p′) for ` = 1, 2. In order to investigate if this
assumption holds at least approximately we construct a test for the hypotheses
K0 : max
i=1,...,p′
|β1,i − β2,i| ≥ δ versus K1 : max
i=1,...,p′
|β1,i − β2,i| < δ, (2.14)
where δ denotes the equivalence margin. To be precise let βˆ(`) denote the least squares
estimates in model m` for the sample {Y`,i,j : j = 1, . . . , n`,i, i = 1, . . . , k`} (` = 1, 2), and
assume that for large sample considerations the sample sizes n` and n`,i converge to infinity
such that
lim
n`→∞
n`,i
n`
= ζ`,i > 0 , i = 1, . . . , k` , ` = 1, 2, (2.15)
lim
n1,n2→∞
n
n1
= λ ∈ (1,∞). (2.16)
Under standard assumptions, which are listed in Section 6 it can be shown that the least
squares estimate βˆ(`) of the parameter β` in model m` is approximately normal distributed,
that is
√
n`(βˆ
(`) − β`) D→ N (0,Σ−1` ) , ` = 1, 2, (2.17)
where the symbol
D−→ means convergence in distribution and the matrix Σ` is defined by
Σ` =
1
σ2`
k∑`
i=1
ζ`,i
∂
∂b`
m`(d`,i,, b`)
∣∣
b`=β`
(
∂
∂b`
m`(d`,i,, b`)
∣∣
b`=β`
)T
, ` = 1, 2. (2.18)
Here and throughout this paper we assume that the matrices Σ1 and Σ2 are non-singular.
Consequently the difference
√
n(βˆ(1) − βˆ(2)) is also asymptotically normal distributed, and
in particular it follows for the first p′ components of the difference that
√
n
(
(βˆ1,1, . . . , βˆ1,p′)− (βˆ2,1, . . . , βˆ2,p′)−
(
(β1,1, . . . , β1,p′)− (β2,1, . . . , β2,p′)
)) D→ N (0,Ω),
(2.19)
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where the matrix Ω is defined by
Ω := λΛ−11 +
λ
λ−1Λ
−1
2 , (2.20)
Λ−1` =
(
(Σ−1` )ij)
)p′
i,j=1
denotes the upper-left p′ × p′-block of the matrix Σ−1` (` = 1, 2) and
λ is defined in (2.16). Therefore we obtain the approximation
(βˆ1,1, . . . , βˆ1,p′)− (βˆ2,1, . . . , βˆ2,p′) D≈ N ((β1,1, . . . , β1,p′)− (β2,1, . . . , β2,p′), 1nΩ) ,
where Ω is defined in (2.20). We can now apply the test (2.2) proposed in Wang et al.
(1999) by rejecting the null hypothesis K0 in (2.14), whenever
|βˆ1,i − βˆ2,i| < δ − t1−α,n−2
(
Ωˆii
n(n−2)
)1/2
for all i = 1, . . . , p′, (2.21)
where t1−α,n−2 denotes the 1−α quantile of the t-distribution with n−2 degrees of freedom
and Ωˆii the ith diagonal element of the matrix Ωˆ which is an estimate for the (unknown)
covariance matrix Ω (this is obtained by replacing the unknown parameters β`, σ
2
` and
weights ζ`,i in (2.18) by their corresponding estimates and n`,i/n`, respectively).
3 Finite sample properties
We now investigate the finite sample properties of the bootstrap test proposed in Section
2.2 in terms of power and size using numerical simulations. The data is generated as follows:
(a) We choose the functional form of the models m1,m2 and specify their parameters
β1, β2 (including a common parameter β0), which determine the true underlying
models. Further we choose variances σ2` and the actual dose levels d`,i, ` = 1, 2.
(b) For each dose d`,i we calculate n`,i values for the response given by m`(d`,i, (β0, β˜`)).
By generating residual errors η`,i,j ∼ N(0, σ2` ) we obtain the final response data
Y`,i,j = m`(d`,i, (β0, β˜`)) + η`,i,j, j = 1, . . . , n`,i, i = 1, . . . k`, ` = 1, 2. (3.1)
The simulation results below were obtained using 1′000 simulation runs, where B = 500
bootstrap replications were used to calculate quantiles of the bootstrap test.
In the following, we report the simulations results for power and size under three different
scenarios. We consider the four-parameter sigmoid Emax model
m(d, β) = β1 +
β2d
β3
ββ34 + d
β3
, (3.2)
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which is frequently used in practice when modeling dose response relationships (see for
example Gabrielsson and Weiner (2007) or Thomas et al. (2014)). In model (3.2) the
parameter β = (β1, β2, β3, β4) corresponds (in this order) to the placebo effect E0, the
maximum effect Emax, the Hill parameter h determining the steepness of the dose-response
curve and the dose ED50 producing half of the maximum effect (Macdougall (2006)). In
what follows we add an index ` = 0 for a shared parameter or ` = 1, 2 for the group under
consideration.
Scenario 1: We assume the dose range D = [0, 4] with identical dose levels d`,i = i − 1,
i = 1, 2, 3, 4, 5 for both regression models ` = 1, 2. For each configuration of σ2` = 1, 2, 3
we use (3.1) to simulate n`,i = 6, 18, 30 observations at each dose level d`,i, resulting in
total sample sizes of n` = 30, 90, 150, respectively. We first compare the two sigmoid Emax
models
m1(d, β1) = β0,1 +
β0,2d
β0,3
β˜
β0,3
1,4 + d
β0,3
and m2(d, β2) = β0,1 +
β0,2d
β0,3
β˜
β0,3
2,4 + d
β0,3
. (3.3)
assuming the shared parameters (β0,1, β0,2, β0,3). The only difference between the two mod-
els is in the ED50 parameters β˜1,4 and β˜2,4, which results in the need to estimate five
parameters in total. We consider the reference sigmoid Emax model m1 with the pa-
rameters (β0,1, β0,2, β0,3) = (1, 5, 4) and β˜1,4 = 1. This reference model is compared to
various specifications of the second model m2 determined by β˜2,4 = 1.99, 1.77, 1.59, 1.43,
1.37, 1 and common shared parameters (β0,1, β0,2, β0,3). The values for β˜2,4 were chosen
such that the maximum absolute distances d∞ = maxd∈D |m2(β2, d)−m1(β1, d)| are given
by 2, 1.5, 1, 0.5, 0.25, 0 respectively. For d∞ > 0 these are attained at the dose lev-
els 1.61, 1.52, 1.44, 1.37 and 1.33; see Figure 1a. For d∞ = 0, that is β˜1,4 = β˜2,4, the
maximum distance is attained at every point in D.
In Table 1 we summarize the simulated rejection probabilities of the bootstrap test (2.9)
under the null hypothesis (2.4) with d∞ = 2, 1.5, 1 and ε = 1. We conclude that the
bootstrap test controls its level in all cases under consideration. At the margin of the null
hypothesis (i.e. d∞ = 1) the approximation of the level is very precise, even for sample
sizes as small as n`,i = 6.
We also investigated the relative residual mean squared errors (RRMSE) of the parameters
estimates. Table 2 summarizes the simulation results only for d∞ = 1 (i.e. at the margin of
the null hypothesis), as the results are similar for other choices of d∞. We conclude that the
RRMSE for estimating the Hill parameter β0,3 is (by far) the largest. This phenomenon has
also been observed by Mielke (2016). We also observe that all estimation errors decrease
with larger sample sizes and smaller variances. Table 2 also summarizes the RRMSE
when fixing the Hill parameter at β0,3 = 4 (see the numbers in brackets). In this case,
9
(a) Scenario 1 (b) Scenario 2
0 1 2 3 4
1
2
3
4
5
6
Dose
R
es
po
ns
e
l
l
l
l
l
m1
m2
0 1 2 3 4
1
2
3
4
5
6
Dose
R
es
po
ns
e
l
l
l
l
l
m1
m2
Figure 1: Graphical illustration of Scenarios 1 and 2. Open dots indicate the doses and cor-
responding responses where the maximum distance to the reference curve m1 (dashed line) is
attained.
α = 0.05 α = 0.1
n` d∞ σ2 = 1 σ2 = 2 σ2 = 3 σ2 = 1 σ2 = 2 σ2 = 3
30 2 0.002 (0.000) 0.010 (0.005) 0.012 (0.009) 0.002 (0.004) 0.018 (0.013) 0.031 (0.019)
30 1.5 0.014 (0.013) 0.035 (0.028) 0.027 (0.043) 0.026 (0.020) 0.055 (0.049) 0.052 (0.070)
30 1 0.068 (0.058) 0.054 (0.065) 0.051 (0.060) 0.106 (0.099) 0.109 (0.114) 0.115 (0.121)
90 2 0.000 (0.000) 0.000 (0.000) 0.001 (0.002) 0.000 (0.000) 0.000 (0.000) 0.002 (0.002)
90 1.5 0.004 (0.001) 0.010 (0.006) 0.013 (0.015) 0.005 (0.005) 0.021 (0.014) 0.026 (0.020)
90 1 0.048 (0.071) 0.053 (0.043) 0.062 (0.059) 0.104 (0.122) 0.101 (0.097) 0.129 (0.117)
150 2 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.004)
150 1.5 0.000 (0.000) 0.003 (0.000) 0.002 (0.000) 0.002 (0.000) 0.011 (0.002) 0.012 (0.009)
150 1 0.056 (0.061) 0.040 (0.061) 0.042 (0.063) 0.103 (0.102) 0.090 (0.102) 0.096 (0.109)
Table 1: Simulated Type I error of the bootstrap test (2.9) for the equivalence of two
sigmoid Emax models defined in Scenario 1 with ε = 1. The numbers in brackets show the
simulated Type I error when fixing the Hill parameter at β0,3 = 4.
four parameters need to be estimated in total and the estimation errors become slightly
smaller. We also repeated the Type I error rate simulations when fixing the Hill parameter
at β0,3 = 4. The the results are reported in Table 1 (numbers in brackets) and we conclude
that the size is well controlled within the simulation error.
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n` σ
2 β0,1 β0,2 β0,3 β˜1,4 β˜2,4
30 1 0.288 (0.263) 0.091 (0.062) 0.493 0.125 (0.108) 0.114 (0.106)
30 2 0.389 (0.358) 0.118 (0.090) 0.739 0.174 (0.157) 0.172 (0.148)
30 3 0.460 (0.427) 0.134 (0.105) 0.841 0.228 (0.198) 0.211 (0.185)
90 1 0.166 (0.152) 0.054 (0.036) 0.184 0.067 (0.064) 0.063 (0.061)
90 2 0.237 (0.219) 0.076 (0.054) 0.355 0.107 (0.086) 0.091 (0.086)
90 3 0.280 (0.261) 0.091 (0.062) 0.450 0.130 (0.112) 0.113 (0.105)
150 1 0.123 (0.115) 0.040 (0.029) 0.129 0.050 (0.057) 0.049 (0.046)
150 2 0.171 (0.170) 0.057 (0.041) 0.241 0.073 (0.072) 0.068 (0.063)
150 3 0.219 (0.204) 0.070 (0.050) 0.322 0.095 (0.086) 0.091 (0.084)
Table 2: RRMSE of the parameters obtained in the model estimation step of the bootstrap
test (2.9) for the equivalence of two sigmoid Emax models defined in Scenario 1 with d∞ = 1.
The numbers in brackets show the values for the RRMSE when fixing the Hill parameter at
β0,3 = 4.
In Table 3 we summarize the power of the bootstrap when generating the data under the
alternative d∞ = 0.5, 0.25, 0 and ε = 1. As expected, the power increases with larger
sample sizes and smaller variances and is reasonably high across all configurations. Fixing
the Hill parameter significantly improves the power which can be explained by the difficulty
of estimating this parameter precisely, as discussed above.
α = 0.05 α = 0.1
n` d∞ σ2 = 1 σ2 = 2 σ2 = 3 σ2 = 1 σ2 = 2 σ2 = 3
30 0.5 0.137 (0.154) 0.075 (0.078) 0.070 (0.073) 0.238 (0.266) 0.172 (0.155) 0.137 (0.145)
30 0.25 0.208 (0.190) 0.102 (0.101) 0.081 (0.088) 0.344 (0.349) 0.196 (0.188) 0.152 (0.170)
30 0 0.181 (0.203) 0.105 (0.105) 0.086 (0.092) 0.333 (0.361) 0.196 (0.213) 0.154 (0.154)
90 0.5 0.341 (0.424) 0.180 (0.230) 0.132 (0.153) 0.505 (0.581) 0.311 (0.357) 0.246 (0.279)
90 0.25 0.550 (0.675) 0.249 (0.315) 0.166 (0.190) 0.733 (0.802) 0.428 (0.484) 0.305 (0.348)
90 0 0.664 (0.783) 0.286 (0.353) 0.191 (0.188) 0.822 (0.884) 0.463 (0.562) 0.338 (0.367)
150 0.5 0.481 (0.593) 0.297 (0.359) 0.207 (0.273) 0.635 (0.729) 0.460 (0.502) 0.355 (0.406)
150 0.25 0.826 (0.868) 0.448 (0.569) 0.280 (0.357) 0.902 (0.933) 0.635 (0.719) 0.477 (0.545)
150 0 0.917 (0.961) 0.559 (0.665) 0.342 (0.415) 0.966 (0.989) 0.740 (0.812) 0.520 (0.596)
Table 3: Simulated power of the bootstrap test (2.9) for the equivalence of two sigmoid Emax
models defined in Scenario 1 with ε = 1. The numbers in brackets show the simulated power
when fixing the Hill parameter at β0,3 = 4.
Scenario 2: We maintain the basic settings from Scenario 1. We consider again two
sigmoid Emax models
m1(d, β1) = β0,1 +
β0,2d
β˜1,3
β˜
β˜1,3
1,4 + d
β˜1,3
and m2(d, β2) = β0,1 +
β0,2d
β˜2,3
β˜
β˜2,3
2,4 + d
β˜2,3
. (3.4)
11
but assume now that both, the placebo response β0,1 and the maximum treatment effect β0,2,
are the same. For the reference model we chose (β0,1, β0,2) = (1, 5), β˜1,3 = 4.5 and β˜1,4 = 1.3.
We investigated the maximum distances d∞ = 2, 1.5, 1, 0.5, 0.25, 0, which resulted in the
following parameter configurations for the second model:
(β˜2,3, β˜2,4) = (0.81, 0.86), (β˜2,3, β˜2,4) = (1.4, 1.07), (β˜2,3, β˜2,4) = (2.15, 1.18),
(β˜2,3, β˜2,4) = (3.15, 1.25), (β˜2,3, β˜2,4) = (3.75, 1.28), (β˜2,3, β˜2,4) = (β˜1,3, β˜1,4) = (4.5, 1.3). (3.5)
The maximum distances between the two curves are now attained at the dose levels
0.66, 0.75, 0.83, 0.9 and 0.93; see Figure 1b.
In Table 4 we summarize the simulated rejection probabilities under the null hypothesis
(2.4) for d∞ = 2, 1.5, 1 and ε = 1. We conclude again that the bootstrap test controls
the designated significance level in all cases under consideration. Especially at the margin
d∞ = 1 the simulated Type I error rates are close to the nominal level α. These observations
apply regardless of whether the Hill parameter is estimated or fixed at the true underlying
values given in (3.5).
α = 0.05 α = 0.1
n` d∞ σ2 = 1 σ2 = 2 σ2 = 3 σ2 = 1 σ2 = 2 σ2 = 3
30 2 0.002 (0.000) 0.001 (0.000) 0.001 (0.000) 0.000 (0.005) 0.003 (0.007) 0.006 (0.011)
30 1.5 0.000 (0.001) 0.003 (0.000) 0.008 (0.001) 0.007 (0.033) 0.002 (0.030) 0.016 (0.054)
30 1 0.036 (0.035) 0.044 (0.040) 0.053 (0.039) 0.083 (0.099) 0.110 (0.116) 0.113 (0.112)
90 2 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.002) 0.004 (0.002)
90 1.5 0.000 (0.000) 0.000 (0.000) 0.004 (0.000) 0.000 (0.007) 0.004 (0.021) 0.012 (0.022)
90 1 0.052 (0.057) 0.028 (0.040) 0.016 (0.036) 0.104 (0.113) 0.068 (0.117) 0.056 (0.105)
150 2 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000) 0.000 (0.000)
150 1.5 0.000 (0.000) 0.000 (0.000) 0.004 (0.000) 0.000 (0.000) 0.000 (0.004) 0.004 (0.004)
150 1 0.056 (0.032) 0.036 (0.036) 0.040 (0.036) 0.100 (0.088) 0.080 (0.100) 0.076 (0.088)
Table 4: Simulated Type I error of the bootstrap test (2.9) for the equivalence of two
sigmoid Emax models defined in Scenario 2 with ε = 1. The numbers in brackets show the
simulated Type I error when fixing the Hill parameters at their true underlying values.
In Table 5 we summarize the simulated power of the bootstrap test under the alternative
d∞ = 0.5, 0.25, 0 and ε = 1. As expected, the power decreases for increasing values of
d∞ and for higher variances or smaller sample sizes. One noticeable exception occurs at
d∞ = 0, where in some cases the power is smaller than for d∞ = 0.25. This effect can
be explained theoretically when considering the proofs for the bootstrap test. In case of
d∞ = 0 the set E = E+∪E− containing all points where the maximum distance between the
two curves is attained (see Appendix 6.3) consists of the entire dose range D. Therefore, the
asymptotic distribution of the test statistic is not Gaussian but a maximum of Gaussian
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processes. This complex structure of the asymptotic distribution has an impact on the
bootstrap procedure and explains the decrease in power for d∞ = 0. This phenomenon
can also be observed, although to a lesser degree, in Scenario 1. Finally, we observe higher
power values when fixing the Hill parameter compared to the situation where it has to be
estimated.
α = 0.05 α = 0.1
n` d∞ σ2 = 1 σ2 = 2 σ2 = 3 σ2 = 1 σ2 = 2 σ2 = 3
30 0.5 0.130 (0.147) 0.096 (0.075) 0.094 (0.072) 0.231 (0.245) 0.191 (0.133) 0.174 (0.125)
30 0.25 0.156 (0.194) 0.102 (0.089) 0.087 (0.085) 0.275 (0.319) 0.197 (0.178) 0.157 (0.147)
30 0 0.155 (0.164) 0.108 (0.076) 0.087 (0.059) 0.310 (0.316) 0.197 (0.166) 0.189 (0.137)
90 0.5 0.312 (0.542) 0.124 (0.225) 0.140 (0.133) 0.528 (0.697) 0.240 (0.384) 0.260 (0.240)
90 0.25 0.384 (0.689) 0.224 (0.289) 0.164 (0.173) 0.560 (0.841) 0.396 (0.484) 0.292 (0.313)
90 0 0.448 (0.663) 0.192 (0.259) 0.148 (0.163) 0.616 (0.807) 0.372 (0.455) 0.240 (0.309)
150 0.5 0.528 (0.780) 0.220 (0.392) 0.160 (0.228) 0.688 (0.896) 0.404 (0.632) 0.256 (0.400)
150 0.25 0.724 (0.904) 0.320 (0.544) 0.260 (0.304) 0.824 (0.936) 0.540 (0.740) 0.408 (0.516)
150 0 0.644 (0.920) 0.308 (0.580) 0.224 (0.248) 0.800 (0.956) 0.532 (0.728) 0.404 (0.484)
Table 5: Simulated power of the bootstrap test (2.9) for the equivalence of two sigmoid Emax
models defined in Scenario 2 with ε = 1. The numbers in brackets show the simulated power
when fixing the Hill parameters at their true underlying values.
Scenario 3: We now investigate the operating characteristics of the bootstrap test as-
suming three, two, one and no shared parameters. We set ε = 1, α = 0.05 and compare
again two sigmoid Emax models. The true placebo response is chosen as β1,1 = β2,1 = 0.
The reference model m1 is specified by (β1,2, β1,3, β1,4) = (5, 2, 1.3). The second model is
specified by (β2,2, β2,3, β1,4) = (5, 2, κ), where κ ∈ (1.3, 3] is chosen such that the maximum
distances with respect to m1 lie between 0 and 2; see the resulting curves plotted in Figure
2(a) for κ = 1.5, 1.7, 2, 2.5, 3. Consequently the parameters specifying the two models only
differ in ED50 parameters β˜1,4 and β˜2,4 and the maximum distance is determined by the
choice of κ. As all other parameters are the same for the two models, we can compare the
bootstrap test assuming three, two, one and no shared parameter. Note that we do not
consider the case of identical models (i.e. κ = 1.3) because of the discontinuity of power at
d∞ = 0 described under Scenario 2. The dose range is given by D = [0, 10] with 5 different
dose levels d`,1 = 0, d`,2 = 1, d`,3 = 2, d`,4 = 5, d`,5 = 10, ` = 1, 2. We create n`,i = 35
observations at each dose level for each group according to (3.1), which results in a total
sample size of n = n1 + n2 = 350. Finally, we choose σ
2
` = 2, ` = 1, 2.
In Figure 2(b) we plot the proportion of rejections in dependence of the true maximum
absolute difference d∞ ∈ (0, 2]. Under the null hypothesis d∞ ≥ 1 all four tests control
their level, as the proportion of rejections is smaller than or equal to α = 0.05 within
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Figure 2: (a) Graphical illustration of the regression functions m1 and m2 with κ =
1.5, 1.7, 2, 2.5, 3 in Scenario 3. (b) Proportion of rejections in dependence of the true maximum
absolute difference d∞ for four different tests assuming one, two, three and no shared parameters
for ε = 1 (vertical dotted line) and α = 0.05 (horizontal dashed line).
simulation errors. Looking at the region d∞ < 1, we observe that the test assuming
three shared parameters has the highest power among all four tests, followed by the test
assuming two shared parameters. The difference between the tests assuming one and no
shared parameter is rather small. Concluding, the more parameters can be assumed to be
common for the two regression curves the higher is the power of the test. Note, however,
that strictly speaking the hypotheses (2.4) are different when assuming three, two, one
and no shared parameters and that the perceived power gain when assuming more shared
parameters comes at the cost of making additional assumptions that need to be verified in
practice, as illustrated with the clinical trial example in Section 4.
4 Clinical trial example
We now illustrate the proposed method with a multi-regional clinical trial example. The ob-
jective of this trial is to evaluate the dose response relationships in Caucasian and Japanese
patients and assess their similarity. Based on data from previous clinical trials investigat-
ing a drug with a similar mode of action, it is reasonable to assume a similar response
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to placebo and a common maximum treatment effect in both populations, with the main
difference expected to be in a different onset of treatment effect. Using the sigmoid Emax
model (3.2), these consideration thus lead to different ED50 and Hill parameters for the
two dose response curves. Because the trial is still at its design stage, we simulate data
based on the trial assumptions. To maintain confidentiality, we scale the actual doses to lie
within the [0, 15] interval. These limitations do not change the utility of the calculations
below.
We assume 60 Japanese and 240 Caucasian patients, resulting in 300 patients overall.
Patients from both populations are randomized to receive either placebo (dose level 0) or
one of three active dose levels, namely 1, 3, 15 for the Japanese and 0.5, 9 and 15 for the
Caucasian patients. Assuming equal allocation of patients within each population, we thus
have 75, 60, 15, 15, 60, and 75 patients randomized to the dose levels 0, 0.5, 1, 3, 9 and
15, respectively. The response variable is assumed to be normally distributed and larger
values indicate a better outcome. Pharmacological and clinical considerations suggest the
use of the (three-parameter) Emax model with the Hill parameter fixed at 1. Later on we
relax this assumption as part of a sensitivity analysis. The R code for this example and all
other calculations in this paper is available from the authors upon request.
In Figure 3 we display the fitted dose response models m1(d, βˆ1) and m2(d, βˆ2) for the
Japanese and Caucasian patients, respectively, together with the individual observations,
where d ∈ [0, 15] and the y-axis is truncated to [−1, 6] for better readability. The param-
eter estimates from the two separate model fits are given by βˆ1 = (−0.195, 4.751, 11.991)
and βˆ2 = (−0.002, 5.676, 33.887). The observed differences for the placebo response and
the maximum treatment effect are given by |βˆ1,1 − βˆ2,1| = 0.193 and |βˆ1,2 − βˆ2,2| = 0.925,
respectively, and thus relatively small, as it also transpires from the plots in Figure 3. To
corroborate this empirical observation, we formally test whether the assumption of shared
parameters is plausible by applying the equivalence test described in Section 2.3 on the data
set under consideration. We choose the threshold δ = 1.5 and therefore test the null hypoth-
esis K0 : maxi=1,2 |β1,i − β2,i| ≥ 1.5 against the alternative K1 : maxi=1,2 |β1,i − β2,i| < 1.5.
Applying the test (2.21) for α = 0.05, we obtain Ωˆ11 = 3127.91 and Ωˆ22 = 10748.27 and
therefore δ − t1−α,n−2
(
Ωˆ11
n(n−2)
)1/2
= 1.191 and δ − t1−α,n−2
(
Ωˆ22
n(n−2)
)1/2
= 0.928, respectively.
We can thus reject K0 at the relatively stringent 5% level and conclude equivalence of the
two parameters, which justifies using the bootstrap test (2.1) with shared parameters.
We now evaluate the similarity of the dose response curves for the Japanese and Caucasian
patients, assuming the same placebo and maximum treatment effect. In order to compute
the non-linear least squares estimates in model (2.1) with (2.2) we formulate the objective
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Figure 3: Fitted Emax model m1 (m2) for the Japanese (Caucasians) patients given by the solid
(dashed) line with observations marked by “o” (“x”).
function of the minimization step as
4∑
i=1
60∑
j=1
(
Y1,i,j −
(
β0,1 +
β0,2d1,i,j
β˜1,3 + d1,i,j
))2
+
4∑
i=1
240∑
j=1
(
Y2,i,j −
(
β0,1 +
β0,2d2,i,j
β˜2,3 + d2,i,j
))2
.
Here, β0,1 denotes the (shared) placebo effect, β0,2 the (shared) maximum treatment ef-
fect Emax, and β˜1,3 and β˜2,3 the ED50 parameters of the two models. Using the auglag
function from the alabama package Varadhan (2014) to solve the above optimization prob-
lem, we obtain the parameter estimates βˆ0,1 = −0.064 (0.074), βˆ0,2 = 5.366 (0.137),
ˆ˜β1,3 = 19.400 (2.634) and
ˆ˜β2,3 = 25.681 (3.256). In brackets we report the associated
standard errors, which have to be calculated manually based on (5.5). The estimates for
the population variances are σˆ21 = 0.508 and σˆ
2
2 = 0.455. The observed maximum differ-
ence between both curves over the investigated dose range [0, 15] is dˆ∞ = 0.376, attained
at dose 2.23. We apply the bootstrap test (2.9) using B = 1′000 bootstrap replications.
Setting ε = 0.7 for the equivalence margin in (2.4), we obtain the quantile q0.05 = 0.438
for α = 0.05. Thus, we reject the null hypothesis (2.4) at the 5% significance level and
conclude that the dose response curves for the Japanese and Caucasian populations are sim-
ilar, under the shared parameter assumption. Alternatively, we can calculate the p-value
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1
B
∑B
i=1 I(d
∗(i)
∞ ≤ dˆ∞) = 0.023 for the bootstrap test and obtain the same test decision at
level α = 0.05. For illustration purposes we also apply the bootstrap test (2.9) but without
shared parameters (yet under the assumption of a fixed Hill parameter). Accordingly, we
obtain a considerably larger p-value of 0.458, which supports our findings from Scenario 3
in Section 3 about the loss in power when no shared parameters are assumed. In this case
the observed maximum distance is dˆ∞ = 0.706, attained at dose 1.42, and the quantile of
the bootstrap distribution is q0.05 = 0.449.
Finally, we perform a sensitivity analysis to investigate the assumption of the Hill parameter
being equal to 1. As part of this analysis we repeat the model fit and the bootstrap
test using the sigmoid Emax model (3.2) where the Hill parameter is now part of the
estimation. The parameter estimates (standard errors in brackets) are βˆ0,1 = 0.037 (0.082),
βˆ0,2 = 4.544 (0.218),
ˆ˜β1,3 = 1.05 (0.229),
ˆ˜β1,4 = 13.542 (2.095),
ˆ˜β2,3 = 1.650 (0.331) and
ˆ˜β2,4 = 16.558 (4.521). Now, the maximum distance between the curves is dˆ∞ = 0.640,
attained at dose 0.6. It turns out that the standard errors of the estimates are slightly higher
which is in line with the results shown in the simulation studies in Section 3. Performing
again the bootstrap test with two shared parameters results the quantile q0.05 = 0.429
and the p-value 0.285. Consequently, we cannot reject the null hypothesis in this case.
In conclusion, fixing the Hill parameter to 1 and assuming both the placebo effect and
the maximum treatment effect to be the same in both populations clearly results in the
most powerful procedure. We can demonstrate equivalence at the significance level of
α = 0.05, whereas in case of estimating both models separately (i.e. no shared parameters)
or including the Hill parameter in the estimation we obtain considerably larger p-values.
5 Conclusion
In this paper we developed a new test for the equivalence of two regression curves when it
is reasonable to assume that some model parameters are the same. Our approach is based
on an estimate of the maximum deviation between the two curves, where critical values are
obtained by a novel constraint bootstrap procedure. We demonstrated that the new test
controls its level properly and is consistent.
We investigated the finite sample properties of the proposed procedure using extensive
simulations and observed that the Type I error rate is controlled in all scenarios under
consideration, even for sample sizes as small as 6 patients per dose level. Further, we
concluded that the test reaches a reasonable power that increases with larger sample sizes.
In particular, we demonstrated that the power of tests for the equivalence of curves can be
improved substantially by using the additional information of common parameters in the
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two regression curves. This effect could also be observed in the clinical trial example, which
showed the power advantage of the bootstrap test (2.9) if the underlying assumptions are
well justified. Relaxing those assumptions may lead to more robust conclusions, but only
at a cost of a loss in power.
An interesting extension of the proposed methodology arises from the need to include
covariates in clinical trial practice. Covariates can be continuous (e.g. age or body mass
index), categorical (e.g. disease status or race), or binary (e.g. gender or smoking yes/no),
possibly changing over time. These cases may have to be treated differently and we leave
this problem for future research. Another area of research could be the assessment of
similarity in two nested populations, thus relaxing the assumption of independence between
the observations. In our multi-regional clinical trial example we compared the Japanese
with Caucasian patients. It will be interesting and relevant to clinical trials to explore
the development of the proposed methods when comparing the Japanese with an overall
population that includes Japanese and Caucasian patients. Again, we leave this topic for
future research.
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6 Appendix: Proof of Theorem 2.1 and Remark 2.2
The proof of the theoretical results of this paper proceeds in several steps. First we state
the assumptions under which the statements hold (Section 6.1). Second, we derive the
asymptotic distribution of the parameter estimates in models with common parameters
(Section 6.2). In Section 6.3 we derive a result on the weak convergence of a stochastic
process, from which the proof of Theorem 2.1 and Remark 2.2 can be derived (see Section
6.4).
6.1 Assumptions
For the theoretical results of this paper we make the same assumptions as in Dette et al.
(2018).
1. The errors η`,i,j are independent, have finite variance σ
2
` and expectation zero.
2. The covariate region D ⊂ Rd is compact and the number and location of dose levels
k` does not depend on n`, ` = 1, 2.
3. All estimates of the parameters β1, β2 are computed over compact sets B1 ⊂ Rp1 and
B2 ⊂ Rp2 .
4. The regression functions m1 and m2 are twice continuously differentiable with respect
to the parameters for all b1, b2 in neighbourhoods of the true parameters β1, β2 and all
d ∈ D. The functions (d, b`) 7→ m`(d, b`) and their first two derivatives are continuous
on D ×B`.
5. The gradients with respect to the parameters are uniformly bounded, that is
supd∈D
∥∥∥ ∂∂β`m`(d, β`)∥∥∥ <∞, ` = 1, 2.
6. Defining ψ
(n)
a,` (b) :=
∑k`
i=1
n`,i
n`
(m`(d`,i, a)−m`(d`,i, b))2, we assume that for any u > 0
there exists a constant vu,` > 0 such that
lim inf
n1,n2→∞
inf
a∈B`
inf
|b−a|≥u
ψ
(n)
a,` (b) ≥ vu,` ` = 1, 2.
6.2 Asymptotic properties of the OLS
In this section we derive the asymptotic normality of the parameter estimates in models
with common parameters. Observing the definition of the OLS βˆ = (βˆ0,
ˆ˜β1,
ˆ˜β2) in (2.3) we
20
obtain, by taking the partial derivatives, βˆ by the necessary conditions
0 =
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(
Y`,i,j −m`(d`,i, (βˆ0, ˆ˜β`))
)(
∂
∂β0
m`(d`,i, β0, β˜`)
∣∣
(β0,β˜`)=(βˆ0,
ˆ˜
β`)
)T
0 =
k∑`
i=1
n`,i∑
j=1
(
Y`,i,j −m`(d`,i, (βˆ0, ˆ˜β`))
)(
∂
∂β˜`
m`(d`,i, β0, β˜`)
∣∣
(β0,β˜`)=(βˆ0,
ˆ˜
β`)
)T
, ` = 1, 2. (5.1)
Defining
h`(d`,i) =
(
∂
∂β0
m`(d`,i, (β0, β˜`))
)T
, h˜`(d`,i) =
(
∂
∂β˜`
m`(d`,i, (β0, β˜`))
)T
hˆ`(d`,i) =
(
∂
∂β0
m`(d`,i, β0, β˜`)
∣∣
(β0,β˜`)=(βˆ0,
ˆ˜
β`)
)T
, ˆ˜h`(d`,i) =
(
∂
∂β˜`
m`(d`,i, β0, β˜`)
∣∣
(β0,β˜`)=(βˆ0,
ˆ˜
β`)
)T
,
for ` = 1, 2 we can write(
∂
∂β
m1(d1,i, β0, β˜1)
∣∣
(β0,β˜1)=(βˆ0,
ˆ˜
β1)
)T
=
(
hˆ1(d1,i),
ˆ˜h1(d1,i), 0p−p′
)
(
∂
∂β
m2(d2,i, β0, β˜2)
∣∣
(β0,β˜2)=(βˆ0,
ˆ˜
β2)
)T
=
(
hˆ2(d2,i), 0p−p′ ,
ˆ˜h2(d2,i)
)
,
where 0 = 0p−p′ denotes the zero vector in Rp−p
′
. Therefore the equations in (5.1) can be
summarized to
0 =
k1∑
i=1
n1,i∑
j=1
(
Y1,i,j −m1(d1,i, (βˆ0, ˆ˜β1))
)(
hˆ1(d1,i),
ˆ˜h1(d1,i), 0p−p′
)T
+
k2∑
i=1
n2,i∑
j=1
(
Y2,i,j −m2(d2,i, (βˆ0, ˆ˜β2))
)(
hˆ2(d2,i), 0p−p′ ,
ˆ˜h2(d2,i)
)T
=
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(
Y`,i,j −m`(d`,i, (βˆ0, ˆ˜β`))
)(
∂
∂β
m`(d`,i, β0, β˜`)
∣∣
(β0,β˜`)=(βˆ0,
ˆ˜
β`)
)T
. (5.2)
A Taylor expansion now yields
0 =
√
n(βˆ − β) 1
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(∂2m`(d`,i,(β0,β˜`))
∂2β
)T
η`,i,j − ∂m`(d`,i,(β0,β˜`))∂β
(∂m`(d`,i,(β0,β˜`))
∂β
)T
+ 1√
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
η`,i,j
(∂m`(d`,i,(β0,β˜`))
∂β
)T
+ oP(1),
and therefore βˆ can be linearized as
√
n(βˆ − β) = 1√
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
η`,i,j
(∂m`(d`,i,(β0,β˜`))
∂β
)T
(5.3)
·
(
− 1n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(∂2m`(d`,i,(β0,β˜`))
∂2β
)T
η`,i,j − ∂m`(d`,i,(β0,β˜`))∂β
(∂m`(d`,i,(β0,β˜`))
∂β
)T)−1
+ oP(1).
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Due to the strong law of large numbers it holds
− 1
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(∂2m`(d`,i,(β0,β˜`))
∂2β
)T
η`,i,j − ∂m`(d`,i,(β0,β˜`))∂β
(∂m`(d`,i,(β0,β˜`))
∂β
)T
a.s−→ 1
λ
k1∑
i=1
ζ1,i
∂m1(d1,i,(β0,β˜1))
∂β
(∂m1(d1,i,(β0,β˜1))
∂β
)T
+ λ−1
λ
k2∑
i=1
ζ2,i
∂m2(d2,i,(β0,β˜2))
∂β
(∂m2(d2,i,(β0,β˜2))
∂β
)T
= Σ˜1 + Σ˜2 =: Σ˜, (5.4)
where the matrices Σ˜1 and Σ˜2 are defined by
Σ˜1 =
1
λ
k1∑
i=1
ζ1,i
(
h1(d1,i), h˜1(d1,i), 0p−p′
)T (
h1(d1,i), h˜1(d1,i), 0p−p′
)
Σ˜2 =
λ−1
λ
k2∑
i=1
ζ2,i
(
h2(d2,i), 0p−p′ , h˜2(d2,i)
)T (
h2(d2,i), 0p−p′ , h˜2(d2,i)
)
,
respectively. Therefore, using the representation in (5.3) and the result in (5.4) we obtain
the asymptotic normality of the estimate, that is
√
n(βˆ − β) D→ N (0, Σ˜−1(σ21Σ˜1 + σ22Σ˜2)Σ˜−1). (5.5)
6.3 Weak convergence of a stochastic process
The essential step in the proof is a result regarding the weak convergence of the process
p˜n(d) = m1(d, (βˆ0,
ˆ˜β1))−m2(d, (βˆ0, ˆ˜β2))− (m1(d, (β0, β˜1))−m2(d, (β0, β˜2))).
We further define ∆˜(d, β) = ∆˜(d, β0, β˜1, β˜2) = ∆˜(d, β1, β2) = m1(d, β1) −m2(d, β2), which
yields p˜n(d) = ∆˜(d, βˆ)− ∆˜(d, β).
Proof. At first we derive a linearization of p˜n by using the Taylor expansion ∆˜(d, βˆ) =
∆˜(d, β) +
(∂∆˜(d,β)
∂β
)T
(βˆ − β)T +R(β), where R(β) is a remainder term and due to (5.3) we
have R(β) = OP(
1
n
). Therefore it holds
√
np˜n(d) =
√
n
(∂∆˜(d,β)
∂β
)T
(βˆ−β)T +oP(1) uniformly
with respect to d ∈ D (note that due to the assumptions ∂∆˜(d,β)
∂β
is continuous in d ∈ D
and D is a compact set) and with the result from (5.3) this can be written as
√
np˜n(x) =
∂∆˜(x,β)
∂β
1√
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
η`,i,j
∂m(x`,i,(β0,β˜`))
∂β
Σ˜−1 + oP(1). (5.6)
Observing (5.3) we define
G˜n(d) =
(∂∆˜(d,β)
∂β
)T
(βˆ − β)T = (∂∆˜(d,β)
∂β
)T( 1
n
2∑
`=1
k∑`
i=1
n`,i∑
j=1
η`,i,j
∂m`(d`,i,(β0,β˜`))
∂β
Σ˜−1
)T
, (5.7)
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and obtain
√
n(p˜n(d)− G˜n(d)) = oP(1). (5.8)
We now define f(d) :=
(
∂∆˜(d,β)
∂β
)T
Σ−1/2, and we consider the map
Φ˜ :
 Rp1+p2−p
′ → `∞(D)
d 7→ (Φ(d) : d 7→ f(d) · d)
Obviously, using the same arguments as before, ∂∆˜(d,β)
∂β
is continuous and therefore the same
holds for Φ˜. Consequently, (5.5) and the Continuous Mapping Theorem (see for example
van der Vaart (2000)[p.7 f.]) yield{√
nG˜n(d)
}
d∈D =
{
Φ˜
(√
nΣ1/2(βˆ − β)T )(d)}
d∈D
D−→ {f(d)Z}
d∈D
D
=
{
G˜(d)
}
d∈D,
uniformly with respect to d ∈ D, where Z ∼ N (0, Ip1+p2−p′), which proves the assertion.
6.4 Proof of Theorem 2.1 and Remark 2.2
The assertion of Theorem 2.1 now follows by the same arguments as given in the proof of
Theorem 4 in Dette et al. (2018). In particular it can be shown that
√
n(d˜∞ − d∞) D−→ Z := max
{
max
d∈E+
G˜(d),max
d∈E−
(−G˜(d))},
where E± = {d ∈ D| m1(d, β1) − m2(d, β2) = ±d∞} denote the sets of extremal points,
that is those points, where the unknown difference m1 −m2 attains it maximum absolute
deviation. The details are omitted for the sake of brevity.
Similarly, note that in the situation of a common placebo group as described in Remark 2.2
the estimates are obtained by minimizing the sum of squares in (2.13). As m0`(0, β˜
0
` ) = 0,
` = 1, 2, this function is the same as the one which is obtained allocating the observations
at placebo arbitrarily to the two groups. More precisely, we can also write the sum of
squares in (2.13) as
2∑
`=1
k∑`
i=1
n`,i∑
j=1
(
Y`,i,j − (b0,1 + b˜`,1 ·m0`(d`,i, b˜0`))
)2
,
where Y1,1,j = Y0,j (j = 1, . . . , n1,1) and Y2,1,j = Y0,j (j = n1,1 +1, . . . , n1,1 +n2,1 = n0). This
corresponds to the minimzation of the sum of squares in (2.3) with a common intercept b0,1,
and consequently this situation can be treated in the same way as considering two different
placebo groups with a common intercept b0,1. By the same arguments as given in Appendix
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6.2 the corresponding estimates are asymptotically normal distributed (if n1,1/n→ c1 and
n2,1/n → c2 for some constants c1, c2,∈ (0, 1)), and the proof in Section 6.3 shows that
Theorem 2.1 remains valid in the model with a common placebo group. As a consequence
we obtain the claim in Remark 2.2
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